17 Jan JangoBio joins Madison’s growing stem cell industry
A new company entering Madison’s booming stem cell industry promises a line of therapy that could stop some of the negative impacts of aging.
JangoBio, a University of Wisconsin-connected biotech that announced its launch at the end of 2016, is refining a stem cell-based solution for restoring the flow of hormones in aging patients. Through its so-called “next-generation” hormonal replacement therapy, the company says that it could help prevent diseases like Alzheimer’s and diabetes, along with other aging-related issues like weight gain and fatigue.
The problem JangoBio targets is the death of testicular and ovarian cells, an aspect of aging that affects hormonal production. Such hormonal changes have been linked to various diseases and negative health outcomes, including an increased risk of mortality.
“There’s loads of evidence for this. It’s not something that’s disputed,” said Bill Kohl, JangoBio’s chief operating officer. “The trick is, how do you get all the hormones balanced? And how do you balance them individually for each person?”
Sorry, the comment form is closed at this time.